Lunit and Leica Launch AI Biomarker 'Lunit SCOPE PD-L1 CAL10'

Medical artificial intelligence (AI) company Lunit announced on May 27 that it has launched an AI-based PD-L1 biomarker solution in partnership with Leica Biosystems (Leica), a global leader in cancer diagnosis and digital pathology.

Lunit and Leica entered into a collaboration in March to develop digital pathology solutions. As the first outcome of this partnership, they have released the "Lunit SCOPE PD-L1 CAL10" solution for the research-oriented exploration and analysis of the PD-L1 biomarker in non-small cell lung cancer.

This solution is optimized for Leica’s PD-L1 antibody "CAL10" and enables rapid and quantitative analysis of the lung cancer biomarker PD-L1 CAL10. This helps to reduce inter-observer variability, shorten diagnostic and analysis times, and ultimately enhances both consistency and efficiency.

The Lunit SCOPE PD-L1 CAL10 can be immediately used through an integrated workflow linked to Leica’s Aperio GT 450 digital pathology scanner.

Karan Arora, Senior Vice President of Advanced Staining, AI & Pharma Partnerships at Leica, stated, "With this product launch, we are now able to support seamless biomarker analysis work in digital pathology research environments," adding, "Our long-term goal is to help researchers use AI solutions more efficiently."

Lunit CEO Bumseok Seo commented, "Through this collaboration, we will continue to expand the use of AI-based biomarker solutions in the field of digital pathology research," and added, "Building on the launch of this AI solution, we plan to further strengthen our position in the global digital pathology and precision oncology markets."

This content was produced with the assistance of AI translation services.